Advanced searches left 3/3

Spectrum - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 09 September 2022

* If you want to update the article please login/register

Cognitive Neuroscience of Autism Spectrum Disorders

Objective: The primary aim of the proposed studies is to use neuroimaging and neuropsychological techniques to discover cognitive idiosyncrasies of individuals on the autism spectrum and their neural underpinnings throughout childhood and adulthood.

Source link: https://clinicaltrials.gov/ct2/show/NCT01031407


Family Study of Affective and Anxiety Spectrum Disorders

Objective: The main aim of this research is to determine the endophenotypes of the spectrum of mood disorders using the techniques of genetic epidemiology, developmental psychopathology, and clinical psychiatry/psychology. In defining subtypes of mood disorders, the key research questions in defining subtypes of mood disorders are focused on the specificity of familial transmission of the mood disorder spectrum and the role of comorbidity with anxiety disorders and migraine syndromes. Approximately 2750 first-degree adult relatives and spouses, as well as 350 child offspring, will participate in the family research component. This report uses a retrospective cohort study to determine the correlation between mood and other mental and physical disorders in probands and their families. The DSM-IV standards, as well as the spectrum of mood disorders and comorbid conditions, will be gathered by assessment tools. Outcome Measures: The primary outcome indicator is the familial aggregation of mood disorder subtypes and their co-aggregation with migraine and anxiety disorders with diagnoses, which is based on scientific investigation of the diagnostic interviews, family history data, and medical analysis of participants using traditional family study methods of association. Secondary findings include correlations between mood disorders and the results obtained from lab, biological, and functional assessments that have been part of the clinical research and their familial correlations. Moving forward, these data will be collected as part of a new protocol and linked to the interview and mobile assessment data obtained in this protocol.

Source link: https://clinicaltrials.gov/ct2/show/NCT00071786


Broad-spectrum Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in In Vitro Human Whole-blood Assay (hWBA)

PGH2 is the inducible PG terminal synthase that functions downstream of COX-2 and catalyzes the conversion of intermediate COX endoperoxide compound PGH2 to PGE2. Both PGE2 reduction and increase of PGI2 in mPGES-1-/- mice result from the rediversion of the stored PGH2 substrate to PGI2 synthase. We have also shown that mPGES-1-deficiency does not cause airway inflammation or airway hyperresponsiveness in an ozone-induced airway inflammation or airway hyperresponsiveness, indicating that pharmacological inhibition of mPGES-1 and endoperoxide rediversion to PGD2 may not cause airway hypersensitivity, not necessarily lead to airway dysfunction. These results, taken together, show that pharmacological inhibition of mPGES-1 may have anti-inflammatory benefits from PGE2 suppression, but that PGI2 administration can reduce the cardiovascular risks associated with selective COX-2 inhibitors. PGI2 is the most common substrate rediversion drug in mice that lack mPGES-1 in endothelial cells or vascular smooth muscle cells, according to our reports, whereas deletion of mPGES-1 in myeloid cells leads to PGH2 shunting predominantly toward TxA2. The determination of baseline lipid levels in pre-stimulated whole blood, determination of lipids in pre-stimulated whole blood treated with a single intervention drug, and quantitation of lipids in pre-stimulated whole blood assays will be included in a variety of intervention compounds.

Source link: https://clinicaltrials.gov/ct2/show/NCT02095288


Delineating the Molecular Spectrum and the Clinical, Imaging and Neuronal Phenotype of Chopra-Amiel-Gordon Syndrome

Heterozygous function variants in ANKRD17 were recently implicated in a newly identified rare intellectual disability disorder disorder. Intriguingly, although it was found that expressive language delay was more noticeable than other developmental measures, no one was able to establish this study with standardized patient testing. Currently, the effect of ANKRD17 haploinsufficiency on human neuronal morphology / excitability is unclear, and, in turn, the correlation of this neuronal phenotype to the clinical neurodevelopmental profile is uncertain. The design of longitudinal studies and the design of clinical trial endpoints will be based on this cross-sectional study. The generation of patient-specific iPSC lines and isogenic controls will enable future studies to develop neuronal populations from clinically characterized patients, filling the knowledge gap on the disorder's biological underpinnings and possibly advancing to biomarkers that reflect specific disturbed neurodevelopmental pathways.

Source link: https://clinicaltrials.gov/ct2/show/NCT05528744


Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Sur-gery - the Prospective-randomized, Microbiologist-blinded, Stratified, Superiority Trials - BAPTIST Trials

In addition, orthopedic surgeons treating limited patient populations are at a high risk of prophylactic-resistant pathogens, or pathogens that are unresponsive to current therapeutic antibiotic therapy regimens. Both Gram-positive skin pathogens and as well as resistant Gram-negative rods will be covered in this selection, from a microbiological viewpoint. As a control, selected multimorbid patients are undergoing spine surgery in selected multimorbid patients; and intraoperative antibiotic prophylaxis in a few instances of orthopedic surgery: tumor surgical dehiscent wounds, debridement under antibiotics, open fractures, and skin colonization with multidrug-resistant bacteria. The investigators alternately randomize the standard prophylaxis to a new broad-spectrum single-shot of gentamicin 5 mg/kg intravenously, awaiting eventual intraoperative testing. According to the planned position in the operating theatres, the investogators would randomly assign surgical interventions defined by the inclusion criteria in a prospective-changing scheme. Vancomycin and gentamicin will be used alone or with the introduction of the single-shot broad-spectrum prophylaxis regimen composed of vancomycin and gentamicin. If a patient is debrided multiple times, he/she can have different prophylaxis regimens for each of the therapies. The clinicians are able to continue with a targeted or empirical therapeutic antibiotic regimen after the prophylactic regimen.

Source link: https://clinicaltrials.gov/ct2/show/NCT05502380


Development of an Epigenetic Biomarker for Prediction of Fetal Alcohol Spectrum Disorder

Fetal alcohol spectrum disorders are a group of disorders that can affect a person whose birth mother consumed alcohol during pregnancy. In addition, the dried blood spots would be used to establish the use of screening assays that use epigenetic changes as indicators of prenatal alcohol exposure. Epigenetic changes in DNA that influence DNA structure and DNA integrity can alter DNA structure, but not change DNA sequence. The use of PEth testing would enable the correlation of prenatal alcohol intake levels with epigenetic changes.

Source link: https://clinicaltrials.gov/ct2/show/NCT03494738


Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder

The aim of this study is to determine the effectiveness of folinic acid in the treatment of language disorders in children with autism spectrum disorder. Folinic acid may be helpful in addressing language difficulties in children with autism spectrum disorder, but this is not known. The main ASD issue of social communication can also be addressed by delayed language enhancements. The study will also focus on the identification of biomarkers in pre-specified subgroups of children with ASD that may have a moderate positive response to folinic acid. The study findings show that high-dose folinic acid will increase vocabulary and set the tone for improved social interaction in children with ASD and moderate language impairment. Under double-blind conditions, 134 children with ASD and moderate language will be randomly assigned folinic acid or placebo for 12 weeks to see if folinic acid is superior to placebo. To determine whether folinic acid is superior to placebo, 134 boys with ASD and moderate language will be randomly assigned either folinic acid or placebo for 134 children with ASD and moderate language.

Source link: https://clinicaltrials.gov/ct2/show/NCT02839915

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions